Brief: Lepu Biopharma Says Exclusive License Agreement For Novel Adc Mrg007
22/01/2025 01:39
Jan 22 (Reuters) - Lepu Biopharma 2157.HK :
* EXCLUSIVE LICENSE AGREEMENT FOR NOVEL ADC MRG007
* DEAL WITH ARRIVENT BIOPHARMA, INC
Further company coverage: 2157.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal